Cardiac safety of systemic therapy in breast cancer patients with high risk of atherosclerosis complications. (March 2017)

• Record Type: Journal Article
• Authors: Matyszewski, Arthur; Czarnecka, Anna M; Stachowiak, Paweł; Nowakowska, Marta; Kornacewicz-Jach, Zdzisława; Kasprzak, Jarosław D; Szczylik, Cezary
• Is Part Of: Future oncology. Volume 13:Number 7(2017)
• Page Start: 593
• Page End: 602
• Publication Date: 2017-03
• Subjects: anthracyclines -- atherosclerosis -- breast cancer -- cardioprotection -- cardiotoxicity -- chemotherapy-related cardiac dysfunction -- coronary disease -- heart failure -- taxanes -- trastuzumab; Oncology -- Periodicals; 616.99405
• DOI: 10.2217/fon-2016-0425
• Languages: English
• ISSNs: 1479-6694

Abstract

Aim: This study was designed to verify the efficacy of breast cancer treatment and its cardiac toxicity in population with significant cardiac comorbidities.Materials & methods: Prospective observational study was conducted in 48 patients.Results: The increase and dependence of echocardiographic parameter early/late were observed on hemoglobin level in all patients, and white blood cells and cholesterol in patients with diabetic were reported. Patients undergo left ventricle diameter change on treatment.Conclusion: Use of potentially cardiotoxic chemo regimens in breast cancer patients with cardiac comorbidities, with optimized cardiac therapy accordingly can save patients from development of early myocardial dysfunction induced by chemotherapy – limiting factor to minimize the risk is optimization of lipid level, red blood cell count and platelets count.